数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Derek Newell Director and President 49 221.21万美元 未持股 2018-04-23
Michael Eberhard Director 52 18.10万美元 未持股 2018-04-23
Kenny Van Zant Director 48 17.50万美元 未持股 2018-04-23
Seth Cohen Director 38 未披露 未持股 2018-04-23
Ed Park Director 43 19.11万美元 未持股 2018-04-23
John C. Doyle Director and Chief Executive Officer 49 212.08万美元 未持股 2018-04-23
Bryan Roberts Director and Chairman 51 20.32万美元 未持股 2018-04-23
David Ebersman Director 48 18.00万美元 未持股 2018-04-23
David B. Singer Director 55 18.10万美元 未持股 2018-04-23

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Derek Newell Director and President 49 221.21万美元 未持股 2018-04-23
Siobhan Nolan Mangini Chief Financial Officer 37 112.78万美元 未持股 2018-04-23
Eric Chan Chief Accounting Officer 42 未披露 未持股 2018-04-23
John C. Doyle Director and Chief Executive Officer 49 212.08万美元 未持股 2018-04-23

董事简历

中英对照 |  中文 |  英文
Derek Newell

Derek Newell自2017年4月起担任总裁兼董事。他此前曾于2012年1月至2017年4月担任Jiff,Inc.的首席执行官兼董事。纽维尔先生此前曾于2016年7月至2017年1月担任万达公司董事会成员。Newell先生是HT3的创始董事,该公司是一家专注于加速采用数字健康技术的咨询公司。从2011年1月到2011年12月,他曾创立HT3公司,并担任其董事总经理。他曾于2009年1月至2010年12月担任Robert Bosch梦百合的总裁。他曾担任HealthHero Networks公司的首席执行官,以及董事会成员(从2007年3月到2008年12月)(2008年初被Robert Bosch梦百合公司收购)。从2006年11月到2007年3月,他担任Health Hero Networks公司的董事会顾问。2004年3月至2006年11月,他担任LifeMasters Supported梦百合的首席营销官。在此之前,他从2001年8月到2004年3月担任Product,Marketing&Outcome副总裁。他从2000年2月到2001年7月担任WebOS业务开发副总裁。他从1998年5月到1999年2月担任Brown&Toland Medical Group业务发展总监。1996年8月至1999年5月,他是哈斯商学院(Haas School of Business)和加州大学伯克利分校公共卫生学院(UC Berkeley School of Public Health)的学生,获得工商管理硕士学位和硕士学位。在此之前,Newell先生在莱索托南部非洲与美国和平队和世界卫生组织呆了4年。他于1992年获得UC Berkeley的分子生物学学士学位。


Derek Newell has served as President and as a director since April 2017. He previously served as Chief Executive Officer and as a director of Jiff, Inc. from January 2012 until April 2017. Mr. Newell previously served on the board of Wanda, Inc. from July 2016 to January 2017. Mr. Newell is a founding director at HT3 a consulting firm focused on accelerating the adoption of digital health technology. From January 2011 to December 2011 he worked on founding HT3 and served as its managing director. He served as the President of Robert Bosch Healthcare, from January 2009 to December 2010. He served as the CEO of HealthHero Networks and a member of the board from March 2007 to December 2008 acquired by Robert Bosch Healthcare in early 2008. From November 2006 to March 2007 he served as an advisor to the board of Health Hero Networks. He served as Chief Marketing Officer of LifeMasters Supported Healthcare from March 2004 to November 2006. Before that he was the VP of Product, Marketing & Outcomes from August 2001 to March 2004. He was the VP of Business Development for WebOS from February 2000 to July 2001. He was Director of Business Development at Brown & Toland Medical Group from May 1998 to February 1999. He was a student at Haas School of Business and the UC Berkeley School of Public Health from August 1996 to May 1999 where he earned his M.B.A. and M.P.H. degrees. Before that, Mr. Newell spent 4 years in Lesotho Southern Africa with the US Peace Corps and the World Health Organization. He received a B.S. in Molecular Biology from UC Berkeley in 1992.
Derek Newell自2017年4月起担任总裁兼董事。他此前曾于2012年1月至2017年4月担任Jiff,Inc.的首席执行官兼董事。纽维尔先生此前曾于2016年7月至2017年1月担任万达公司董事会成员。Newell先生是HT3的创始董事,该公司是一家专注于加速采用数字健康技术的咨询公司。从2011年1月到2011年12月,他曾创立HT3公司,并担任其董事总经理。他曾于2009年1月至2010年12月担任Robert Bosch梦百合的总裁。他曾担任HealthHero Networks公司的首席执行官,以及董事会成员(从2007年3月到2008年12月)(2008年初被Robert Bosch梦百合公司收购)。从2006年11月到2007年3月,他担任Health Hero Networks公司的董事会顾问。2004年3月至2006年11月,他担任LifeMasters Supported梦百合的首席营销官。在此之前,他从2001年8月到2004年3月担任Product,Marketing&Outcome副总裁。他从2000年2月到2001年7月担任WebOS业务开发副总裁。他从1998年5月到1999年2月担任Brown&Toland Medical Group业务发展总监。1996年8月至1999年5月,他是哈斯商学院(Haas School of Business)和加州大学伯克利分校公共卫生学院(UC Berkeley School of Public Health)的学生,获得工商管理硕士学位和硕士学位。在此之前,Newell先生在莱索托南部非洲与美国和平队和世界卫生组织呆了4年。他于1992年获得UC Berkeley的分子生物学学士学位。
Derek Newell has served as President and as a director since April 2017. He previously served as Chief Executive Officer and as a director of Jiff, Inc. from January 2012 until April 2017. Mr. Newell previously served on the board of Wanda, Inc. from July 2016 to January 2017. Mr. Newell is a founding director at HT3 a consulting firm focused on accelerating the adoption of digital health technology. From January 2011 to December 2011 he worked on founding HT3 and served as its managing director. He served as the President of Robert Bosch Healthcare, from January 2009 to December 2010. He served as the CEO of HealthHero Networks and a member of the board from March 2007 to December 2008 acquired by Robert Bosch Healthcare in early 2008. From November 2006 to March 2007 he served as an advisor to the board of Health Hero Networks. He served as Chief Marketing Officer of LifeMasters Supported Healthcare from March 2004 to November 2006. Before that he was the VP of Product, Marketing & Outcomes from August 2001 to March 2004. He was the VP of Business Development for WebOS from February 2000 to July 2001. He was Director of Business Development at Brown & Toland Medical Group from May 1998 to February 1999. He was a student at Haas School of Business and the UC Berkeley School of Public Health from August 1996 to May 1999 where he earned his M.B.A. and M.P.H. degrees. Before that, Mr. Newell spent 4 years in Lesotho Southern Africa with the US Peace Corps and the World Health Organization. He received a B.S. in Molecular Biology from UC Berkeley in 1992.
Michael Eberhard

Michael Eberhard自2016年6月起担任Castlight的董事,并担任Concur的总裁,Concur是全球领先的综合旅行和费用管理解决方案和服务提供商。他于2003年加入Concur,并于2016年11月成为总裁。在Concur公司,他曾担任多个职位,包括全球销售和业务开发执行Vice President;全球客户执行Vice President和总经理;亚太地区执行Vice President和总经理。加入Concur之前,Mike是Xign全球销售Vice President、Ariba Vice President和总经理、PeopleSoft教育和政府Vice President和总经理。


Michael Eberhard has served as a director of Castlight since June 2016 and is the President of Concur, the world's leading provider of integrated travel and expense management solutions and services. He joined Concur in 2003 and became President in November 2016. At Concur, he has held roles including Executive Vice President, Worldwide Sales & Business Development; Executive Vice President and General Manager, Global Accounts; and Executive Vice President and General Manager, Asia Pacific. Prior to joining Concur, Mike was Vice President, Worldwide Sales at Xign; Vice President and General Manager for Ariba; and Vice President and General Manager, Education & Government at PeopleSoft.
Michael Eberhard自2016年6月起担任Castlight的董事,并担任Concur的总裁,Concur是全球领先的综合旅行和费用管理解决方案和服务提供商。他于2003年加入Concur,并于2016年11月成为总裁。在Concur公司,他曾担任多个职位,包括全球销售和业务开发执行Vice President;全球客户执行Vice President和总经理;亚太地区执行Vice President和总经理。加入Concur之前,Mike是Xign全球销售Vice President、Ariba Vice President和总经理、PeopleSoft教育和政府Vice President和总经理。
Michael Eberhard has served as a director of Castlight since June 2016 and is the President of Concur, the world's leading provider of integrated travel and expense management solutions and services. He joined Concur in 2003 and became President in November 2016. At Concur, he has held roles including Executive Vice President, Worldwide Sales & Business Development; Executive Vice President and General Manager, Global Accounts; and Executive Vice President and General Manager, Asia Pacific. Prior to joining Concur, Mike was Vice President, Worldwide Sales at Xign; Vice President and General Manager for Ariba; and Vice President and General Manager, Education & Government at PeopleSoft.
Kenny Van Zant

Kenny Van Zant自2016年8月以来一直担任我们的董事会成员。他此前曾担任Asana公司(基于云的SaaS项目管理工具的创造者)的业务主管,在那里他曾领导所有业务功能,包括销售、营销、客户支持和财务。在Asana任职之前,Van Zant先生是SolarWinds公司高级副总裁,首席产品战略家,他在该公司领导市场营销和产品。他也曾担任Motive公司、Broadjump公司和Cisco Systems公司的商业和营销领导职务。他还担任Puppet,IDERA和ITential的董事会成员。


Kenny Van Zant has served on our Board of Directors since August 2016. He previously served as the Head of Business at Asana, the creator of cloud-based SaaS project management tools, where he led all business functions, including sales, marketing, customer support and finance. Prior to his role at Asana, Mr. Van Zant was the Senior Vice President, Chief Product Strategist at SolarWinds, where he led marketing and products. He has also held business and marketing leadership roles at Motive, BroadJump and Cisco Systems. He also serves as a board member for Puppet, Idera and Itential.
Kenny Van Zant自2016年8月以来一直担任我们的董事会成员。他此前曾担任Asana公司(基于云的SaaS项目管理工具的创造者)的业务主管,在那里他曾领导所有业务功能,包括销售、营销、客户支持和财务。在Asana任职之前,Van Zant先生是SolarWinds公司高级副总裁,首席产品战略家,他在该公司领导市场营销和产品。他也曾担任Motive公司、Broadjump公司和Cisco Systems公司的商业和营销领导职务。他还担任Puppet,IDERA和ITential的董事会成员。
Kenny Van Zant has served on our Board of Directors since August 2016. He previously served as the Head of Business at Asana, the creator of cloud-based SaaS project management tools, where he led all business functions, including sales, marketing, customer support and finance. Prior to his role at Asana, Mr. Van Zant was the Senior Vice President, Chief Product Strategist at SolarWinds, where he led marketing and products. He has also held business and marketing leadership roles at Motive, BroadJump and Cisco Systems. He also serves as a board member for Puppet, Idera and Itential.
Seth Cohen

Seth Cohen自2018年1月以来一直担任我们的董事会成员。科恩先生是OODA Health的联合创始人兼总裁,OODA Health是一家梦百合付款人管理公司,由他于2018年共同创立。此前,科恩曾于2010年至2017年担任Castlight的Vice President、销售和联盟。在加入Castlight之前,Cohen先生从2008年到2010年担任麦肯锡公司(McKinsey&Company)的顾问,该公司是一家咨询公司,是其梦百合付款人和供应商业务的成员。Cohen先生拥有哈佛商学院(Harvard Business School)工商管理硕士学位,哈佛肯尼迪学院(Harvard Kennedy School)工商管理硕士学位,以及斯坦福大学(Stanford University)国际关系学学士学位。


Seth Cohen has served on our Board of Directors since January 2018. Mr. Cohen the co-founder and president of Ooda Health, a healthcare payer administration company, which he co-founded in 2018. Previously, Mr. Cohen served as Castlight's vice president, sales and alliances from 2010 to 2017. Prior to joining Castlight, Mr. Cohen served as a consultant for McKinsey & Company, a consulting firm, as a member of their healthcare payer and provider practice from 2008 to 2010. Mr. Cohen holds an MBA from the Harvard Business School, an MPH from the Harvard Kennedy School, and a BA in International Relations from Stanford University.
Seth Cohen自2018年1月以来一直担任我们的董事会成员。科恩先生是OODA Health的联合创始人兼总裁,OODA Health是一家梦百合付款人管理公司,由他于2018年共同创立。此前,科恩曾于2010年至2017年担任Castlight的Vice President、销售和联盟。在加入Castlight之前,Cohen先生从2008年到2010年担任麦肯锡公司(McKinsey&Company)的顾问,该公司是一家咨询公司,是其梦百合付款人和供应商业务的成员。Cohen先生拥有哈佛商学院(Harvard Business School)工商管理硕士学位,哈佛肯尼迪学院(Harvard Kennedy School)工商管理硕士学位,以及斯坦福大学(Stanford University)国际关系学学士学位。
Seth Cohen has served on our Board of Directors since January 2018. Mr. Cohen the co-founder and president of Ooda Health, a healthcare payer administration company, which he co-founded in 2018. Previously, Mr. Cohen served as Castlight's vice president, sales and alliances from 2010 to 2017. Prior to joining Castlight, Mr. Cohen served as a consultant for McKinsey & Company, a consulting firm, as a member of their healthcare payer and provider practice from 2008 to 2010. Mr. Cohen holds an MBA from the Harvard Business School, an MPH from the Harvard Kennedy School, and a BA in International Relations from Stanford University.
Ed Park

自2010年7月,Ed Park一直担任本公司执行副总裁兼首席运营官。2007年3月至2010年6月,他担任技术总监。从1998年到2007年3月,他担任担任首席软件架构师。他担任Castlight Health, Inc., Healthpoint Services Pvt Ltd, and Kyruus, Inc.董事。加入我公司之前,他是Viant公司一位顾问。他获得哈佛学院计算机科学文学学士学位。


Ed Park currently serves on the boards of Castlight and athenahealth and on the Massachusetts Governors Council for IT Initiatives. He also serves as CEO of Devoted Health, a position he has held since March 2017. Prior to that, he served as Executive Vice President and COO of athenahealth, Inc. from July 2010 to March 2017 and as Chief Technology Officer from March 2007 to June 2010 and as Chief Software Architect from 1998 to March 2007. Prior to joining athenahealth, Inc., Mr. Park was a consultant for Viant, Inc. Mr. Park obtained a Bachelor of Arts magna cum laude from Harvard College in Computer Science.
自2010年7月,Ed Park一直担任本公司执行副总裁兼首席运营官。2007年3月至2010年6月,他担任技术总监。从1998年到2007年3月,他担任担任首席软件架构师。他担任Castlight Health, Inc., Healthpoint Services Pvt Ltd, and Kyruus, Inc.董事。加入我公司之前,他是Viant公司一位顾问。他获得哈佛学院计算机科学文学学士学位。
Ed Park currently serves on the boards of Castlight and athenahealth and on the Massachusetts Governors Council for IT Initiatives. He also serves as CEO of Devoted Health, a position he has held since March 2017. Prior to that, he served as Executive Vice President and COO of athenahealth, Inc. from July 2010 to March 2017 and as Chief Technology Officer from March 2007 to June 2010 and as Chief Software Architect from 1998 to March 2007. Prior to joining athenahealth, Inc., Mr. Park was a consultant for Viant, Inc. Mr. Park obtained a Bachelor of Arts magna cum laude from Harvard College in Computer Science.
John C. Doyle

John C. Doyle,他曾担任我们的首席财务官、副总裁、财务主管(2012年11月以来)。此前,他曾担任 Achaogen公司(一家生物制药公司)的首席财务官兼首席运营官(从2009年8月到2012年11月)。加入Achaogen公司之前,他曾担任Genentech公司的负责财务和公司规划的副总裁(从2007年7月到2009年6月)。他此前曾担任Renovis公司的多种职务,包括财务副总裁兼首席财务官(从2002年8月到2006年8月)、负责财务及运营的高级副总裁和首席财务官(从2006年8月到2007年1月),以及负责公司发展的高级副总裁和首席财务官(从2007年1月到2007年6月)。2012年11月以来,他一直担任 Achaogen公司的董事会成员。他是注册会计师,持有California Polytechnic State University, San Luis Obispo的工商管理学士学位,以及加州大学伯克利分校哈斯商学院(the Haas School of Business at the University of California, Berkeley)的工商管理硕士学位。


John C. Doyle has served as Chief Executive Officer and as a director since April 2017. He previously served as President from July 2016 until April 2017 and as Chief Operating Officer from November 2015 until April 2017. Mr. Doyle also served as Chief Financial Officer, Vice President and Treasurer from November 2012 until July 2016. Previously, Mr. Doyle served as Chief Financial Officer and then Chief Operating Officer of Achaogen, Inc., a biopharmaceutical company, from August 2009 to November 2012. Prior to joining Achaogen, Mr. Doyle was Vice President, Finance and Corporate Planning at Genentech, Inc. from July 2007 to June 2009. Mr. Doyle previously served in various roles at Renovis, Inc., from 2002 to June 2007 ultimately as its Senior Vice President of Corporate Development and Chief Financial Officer. Mr. Doyle has been a member of the board of directors of Achaogen since November 2012 and a member of its compensation committee since January 2016. Mr. Doyle holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo, and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
John C. Doyle,他曾担任我们的首席财务官、副总裁、财务主管(2012年11月以来)。此前,他曾担任 Achaogen公司(一家生物制药公司)的首席财务官兼首席运营官(从2009年8月到2012年11月)。加入Achaogen公司之前,他曾担任Genentech公司的负责财务和公司规划的副总裁(从2007年7月到2009年6月)。他此前曾担任Renovis公司的多种职务,包括财务副总裁兼首席财务官(从2002年8月到2006年8月)、负责财务及运营的高级副总裁和首席财务官(从2006年8月到2007年1月),以及负责公司发展的高级副总裁和首席财务官(从2007年1月到2007年6月)。2012年11月以来,他一直担任 Achaogen公司的董事会成员。他是注册会计师,持有California Polytechnic State University, San Luis Obispo的工商管理学士学位,以及加州大学伯克利分校哈斯商学院(the Haas School of Business at the University of California, Berkeley)的工商管理硕士学位。
John C. Doyle has served as Chief Executive Officer and as a director since April 2017. He previously served as President from July 2016 until April 2017 and as Chief Operating Officer from November 2015 until April 2017. Mr. Doyle also served as Chief Financial Officer, Vice President and Treasurer from November 2012 until July 2016. Previously, Mr. Doyle served as Chief Financial Officer and then Chief Operating Officer of Achaogen, Inc., a biopharmaceutical company, from August 2009 to November 2012. Prior to joining Achaogen, Mr. Doyle was Vice President, Finance and Corporate Planning at Genentech, Inc. from July 2007 to June 2009. Mr. Doyle previously served in various roles at Renovis, Inc., from 2002 to June 2007 ultimately as its Senior Vice President of Corporate Development and Chief Financial Officer. Mr. Doyle has been a member of the board of directors of Achaogen since November 2012 and a member of its compensation committee since January 2016. Mr. Doyle holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo, and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
Bryan Roberts

Bryan Roberts于2008年成为公司的共同创办人。他从2008年到2010年担任董事,并自2010年以来担任我们董事会主席。他加入Venrock风险投资公司于1997年并担任公司合作伙伴。他目前担任Ironwood制药公司董事会主席和Zeltiq Aethetics公司以及一些私人公司总裁。他从1999年到2009年在Athenahealth董事会工作, 从2000年到2007年担任XenoPort董事从2003年到2007年担任Sirna Therapeutics董事。从1989年到1992年他在Kidder, Peabody & Co。财务部门工作,该公司是一家经纪公司。他在达特茅斯学院获得化学学士学位并在哈佛大学获得化学与化学生物学博士学位。


Bryan Roberts co-founded Castlight in 2008 served as a director from 2008 to 2010 and has served as the Chairman of Castlight's Board of Directors since 2010. Dr. Roberts joined Venrock, a venture capital firm, in 1997 where he currently serves as a Partner. Dr. Roberts currently serves as the Chairman of the board of directors of Achaogen, Inc. and as a director of Ironwood Pharmaceuticals, Inc., as well as several private companies. Dr. Roberts previously served on the board of directors of athenahealth, Inc. from 1999 to 2009 XenoPort, Inc. from 2000 to 2007 and Sirna Therapeutics, Inc. from 2003 to 2007. From 1989 to 1992 Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts received a B.A. in Chemistry from Dartmouth College and a Ph.D. in Chemistry and Chemical Biology from Harvard University.
Bryan Roberts于2008年成为公司的共同创办人。他从2008年到2010年担任董事,并自2010年以来担任我们董事会主席。他加入Venrock风险投资公司于1997年并担任公司合作伙伴。他目前担任Ironwood制药公司董事会主席和Zeltiq Aethetics公司以及一些私人公司总裁。他从1999年到2009年在Athenahealth董事会工作, 从2000年到2007年担任XenoPort董事从2003年到2007年担任Sirna Therapeutics董事。从1989年到1992年他在Kidder, Peabody & Co。财务部门工作,该公司是一家经纪公司。他在达特茅斯学院获得化学学士学位并在哈佛大学获得化学与化学生物学博士学位。
Bryan Roberts co-founded Castlight in 2008 served as a director from 2008 to 2010 and has served as the Chairman of Castlight's Board of Directors since 2010. Dr. Roberts joined Venrock, a venture capital firm, in 1997 where he currently serves as a Partner. Dr. Roberts currently serves as the Chairman of the board of directors of Achaogen, Inc. and as a director of Ironwood Pharmaceuticals, Inc., as well as several private companies. Dr. Roberts previously served on the board of directors of athenahealth, Inc. from 1999 to 2009 XenoPort, Inc. from 2000 to 2007 and Sirna Therapeutics, Inc. from 2003 to 2007. From 1989 to 1992 Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts received a B.A. in Chemistry from Dartmouth College and a Ph.D. in Chemistry and Chemical Biology from Harvard University.
David Ebersman

David Ebersman 自2011年7月以来担任公司董事。他自2009年9月以来担任首Facebook席财务官,该公司是一家社会公用事业公司。加入Facebook之前,他曾在担任Genentech过各种职务,该公司是一家生物技术公司,包括从2005年3月到2006年1月担任其首席财务官执行副总裁,从2006年1月到2009年4月首席财务官(当Genentech被f . Hoffmann-La罗氏有限公司收购)。加入Genentech之前,他是Oppenheimer投资公司的研究分析师。2009年7月以来他一直是Ironwood Pharmaceuticals董事会成员。他持有布朗大学国际关系和经济学文学学士学位。


David Ebersman has served as a director of Castlight since July 2011. Mr. Ebersman is currently CEO of Lyra Health, Inc., a health care information technology company focused on behavioral health. Previously, Mr. Ebersman served as the Chief Financial Officer of Facebook, Inc., from 2009 through 2014. Prior to joining Facebook, Mr. Ebersman served in various positions at Genentech, Inc., a biotechnology company, including as its Executive Vice President and Chief Financial Officer, Senior Vice President, Product Operations, and Vice President, Product Development. Prior to joining Genentech, Mr. Ebersman was a research analyst at Oppenheimer & Company, Inc., an investment company. Mr. Ebersman has been a member of the board of directors of SurveyMonkey, Inc. since June 2015. Mr. Ebersman holds an A.B. in International Relations and Economics from Brown University and was selected for a Henry Crown Fellowship in 2000.
David Ebersman 自2011年7月以来担任公司董事。他自2009年9月以来担任首Facebook席财务官,该公司是一家社会公用事业公司。加入Facebook之前,他曾在担任Genentech过各种职务,该公司是一家生物技术公司,包括从2005年3月到2006年1月担任其首席财务官执行副总裁,从2006年1月到2009年4月首席财务官(当Genentech被f . Hoffmann-La罗氏有限公司收购)。加入Genentech之前,他是Oppenheimer投资公司的研究分析师。2009年7月以来他一直是Ironwood Pharmaceuticals董事会成员。他持有布朗大学国际关系和经济学文学学士学位。
David Ebersman has served as a director of Castlight since July 2011. Mr. Ebersman is currently CEO of Lyra Health, Inc., a health care information technology company focused on behavioral health. Previously, Mr. Ebersman served as the Chief Financial Officer of Facebook, Inc., from 2009 through 2014. Prior to joining Facebook, Mr. Ebersman served in various positions at Genentech, Inc., a biotechnology company, including as its Executive Vice President and Chief Financial Officer, Senior Vice President, Product Operations, and Vice President, Product Development. Prior to joining Genentech, Mr. Ebersman was a research analyst at Oppenheimer & Company, Inc., an investment company. Mr. Ebersman has been a member of the board of directors of SurveyMonkey, Inc. since June 2015. Mr. Ebersman holds an A.B. in International Relations and Economics from Brown University and was selected for a Henry Crown Fellowship in 2000.
David B. Singer

David B. Singer自2010年6月担任董事。他自2004年12月以来一直在Maverick资本投资公司工作,并在2008年1月成为有限责任股东。他负责公司全球私人投资活动。新中国成立以前,他担任三个医疗产品公司创始人总裁兼首席执行官。从2006年12月至2013年5月他还曾担任加州Pacific Biosciences公司董事会成员,从1993年到2008年担任Affymetrix公司董事会成员,从1998年到2008年担任Corcept Therapeutics董事会成员,从2004年到2006年担任Oscient制药公司董事会成员。他还担任过两个上市公司高级财务官。他担任几家私人卫生保健公司的董事。他在2013年7月被旧金山市长任命为卫生专员和旧金山总医院联合会议委员会成员。他持有耶鲁大学历史学士学位和斯坦福大学MBA学位。


David B. Singer has served on our Board of Directors since June 2010. Mr. Singer has held various positions at Maverick Capital Ltd. or its affiliates, an investment firm, since December 2004 including Managing Partner of Maverick Ventures since February 2015. Previously, Mr. Singer served as the founding President and Chief Executive Officer of three health care companies. He has also served on the board of directors of Pacific Biosciences of California, Inc. from December 2006 to May 2013 Affymetrix, Inc. from 1993 to 2008 Corcept Therapeutics Incorporated from 1998 to 2008 and Oscient Pharmaceuticals Corporation from 2004 to 2006. Mr. Singer has also served as the senior financial officer of two publicly traded companies. Mr. Singer serves on the boards of several private health care companies. Mr. Singer served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee from July 2013 to January 2017. Mr. Singer holds a B.A. in History from Yale University and an M.B.A. from Stanford University.
David B. Singer自2010年6月担任董事。他自2004年12月以来一直在Maverick资本投资公司工作,并在2008年1月成为有限责任股东。他负责公司全球私人投资活动。新中国成立以前,他担任三个医疗产品公司创始人总裁兼首席执行官。从2006年12月至2013年5月他还曾担任加州Pacific Biosciences公司董事会成员,从1993年到2008年担任Affymetrix公司董事会成员,从1998年到2008年担任Corcept Therapeutics董事会成员,从2004年到2006年担任Oscient制药公司董事会成员。他还担任过两个上市公司高级财务官。他担任几家私人卫生保健公司的董事。他在2013年7月被旧金山市长任命为卫生专员和旧金山总医院联合会议委员会成员。他持有耶鲁大学历史学士学位和斯坦福大学MBA学位。
David B. Singer has served on our Board of Directors since June 2010. Mr. Singer has held various positions at Maverick Capital Ltd. or its affiliates, an investment firm, since December 2004 including Managing Partner of Maverick Ventures since February 2015. Previously, Mr. Singer served as the founding President and Chief Executive Officer of three health care companies. He has also served on the board of directors of Pacific Biosciences of California, Inc. from December 2006 to May 2013 Affymetrix, Inc. from 1993 to 2008 Corcept Therapeutics Incorporated from 1998 to 2008 and Oscient Pharmaceuticals Corporation from 2004 to 2006. Mr. Singer has also served as the senior financial officer of two publicly traded companies. Mr. Singer serves on the boards of several private health care companies. Mr. Singer served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee from July 2013 to January 2017. Mr. Singer holds a B.A. in History from Yale University and an M.B.A. from Stanford University.

高管简历

中英对照 |  中文 |  英文
Derek Newell

Derek Newell自2017年4月起担任总裁兼董事。他此前曾于2012年1月至2017年4月担任Jiff,Inc.的首席执行官兼董事。纽维尔先生此前曾于2016年7月至2017年1月担任万达公司董事会成员。Newell先生是HT3的创始董事,该公司是一家专注于加速采用数字健康技术的咨询公司。从2011年1月到2011年12月,他曾创立HT3公司,并担任其董事总经理。他曾于2009年1月至2010年12月担任Robert Bosch梦百合的总裁。他曾担任HealthHero Networks公司的首席执行官,以及董事会成员(从2007年3月到2008年12月)(2008年初被Robert Bosch梦百合公司收购)。从2006年11月到2007年3月,他担任Health Hero Networks公司的董事会顾问。2004年3月至2006年11月,他担任LifeMasters Supported梦百合的首席营销官。在此之前,他从2001年8月到2004年3月担任Product,Marketing&Outcome副总裁。他从2000年2月到2001年7月担任WebOS业务开发副总裁。他从1998年5月到1999年2月担任Brown&Toland Medical Group业务发展总监。1996年8月至1999年5月,他是哈斯商学院(Haas School of Business)和加州大学伯克利分校公共卫生学院(UC Berkeley School of Public Health)的学生,获得工商管理硕士学位和硕士学位。在此之前,Newell先生在莱索托南部非洲与美国和平队和世界卫生组织呆了4年。他于1992年获得UC Berkeley的分子生物学学士学位。


Derek Newell has served as President and as a director since April 2017. He previously served as Chief Executive Officer and as a director of Jiff, Inc. from January 2012 until April 2017. Mr. Newell previously served on the board of Wanda, Inc. from July 2016 to January 2017. Mr. Newell is a founding director at HT3 a consulting firm focused on accelerating the adoption of digital health technology. From January 2011 to December 2011 he worked on founding HT3 and served as its managing director. He served as the President of Robert Bosch Healthcare, from January 2009 to December 2010. He served as the CEO of HealthHero Networks and a member of the board from March 2007 to December 2008 acquired by Robert Bosch Healthcare in early 2008. From November 2006 to March 2007 he served as an advisor to the board of Health Hero Networks. He served as Chief Marketing Officer of LifeMasters Supported Healthcare from March 2004 to November 2006. Before that he was the VP of Product, Marketing & Outcomes from August 2001 to March 2004. He was the VP of Business Development for WebOS from February 2000 to July 2001. He was Director of Business Development at Brown & Toland Medical Group from May 1998 to February 1999. He was a student at Haas School of Business and the UC Berkeley School of Public Health from August 1996 to May 1999 where he earned his M.B.A. and M.P.H. degrees. Before that, Mr. Newell spent 4 years in Lesotho Southern Africa with the US Peace Corps and the World Health Organization. He received a B.S. in Molecular Biology from UC Berkeley in 1992.
Derek Newell自2017年4月起担任总裁兼董事。他此前曾于2012年1月至2017年4月担任Jiff,Inc.的首席执行官兼董事。纽维尔先生此前曾于2016年7月至2017年1月担任万达公司董事会成员。Newell先生是HT3的创始董事,该公司是一家专注于加速采用数字健康技术的咨询公司。从2011年1月到2011年12月,他曾创立HT3公司,并担任其董事总经理。他曾于2009年1月至2010年12月担任Robert Bosch梦百合的总裁。他曾担任HealthHero Networks公司的首席执行官,以及董事会成员(从2007年3月到2008年12月)(2008年初被Robert Bosch梦百合公司收购)。从2006年11月到2007年3月,他担任Health Hero Networks公司的董事会顾问。2004年3月至2006年11月,他担任LifeMasters Supported梦百合的首席营销官。在此之前,他从2001年8月到2004年3月担任Product,Marketing&Outcome副总裁。他从2000年2月到2001年7月担任WebOS业务开发副总裁。他从1998年5月到1999年2月担任Brown&Toland Medical Group业务发展总监。1996年8月至1999年5月,他是哈斯商学院(Haas School of Business)和加州大学伯克利分校公共卫生学院(UC Berkeley School of Public Health)的学生,获得工商管理硕士学位和硕士学位。在此之前,Newell先生在莱索托南部非洲与美国和平队和世界卫生组织呆了4年。他于1992年获得UC Berkeley的分子生物学学士学位。
Derek Newell has served as President and as a director since April 2017. He previously served as Chief Executive Officer and as a director of Jiff, Inc. from January 2012 until April 2017. Mr. Newell previously served on the board of Wanda, Inc. from July 2016 to January 2017. Mr. Newell is a founding director at HT3 a consulting firm focused on accelerating the adoption of digital health technology. From January 2011 to December 2011 he worked on founding HT3 and served as its managing director. He served as the President of Robert Bosch Healthcare, from January 2009 to December 2010. He served as the CEO of HealthHero Networks and a member of the board from March 2007 to December 2008 acquired by Robert Bosch Healthcare in early 2008. From November 2006 to March 2007 he served as an advisor to the board of Health Hero Networks. He served as Chief Marketing Officer of LifeMasters Supported Healthcare from March 2004 to November 2006. Before that he was the VP of Product, Marketing & Outcomes from August 2001 to March 2004. He was the VP of Business Development for WebOS from February 2000 to July 2001. He was Director of Business Development at Brown & Toland Medical Group from May 1998 to February 1999. He was a student at Haas School of Business and the UC Berkeley School of Public Health from August 1996 to May 1999 where he earned his M.B.A. and M.P.H. degrees. Before that, Mr. Newell spent 4 years in Lesotho Southern Africa with the US Peace Corps and the World Health Organization. He received a B.S. in Molecular Biology from UC Berkeley in 1992.
Siobhan Nolan Mangini

Siobhan Nolan Mangini自2016年7月起担任首席财务官。在此之前,她曾于2015年10月至2016年7月担任财务与业务运营Vice President。她于2012年2月加入Castlight,此前曾担任高级董事,负责财务规划和业务运营(从2014年11月到2015年9月),以及战略和业务发展董事(从2012年2月到2014年9月)。加入Castlight公司之前,她曾任职Bain&Company(管理咨询公司)(从2009年到2012年1月),从事医疗保健和私人股本实践。Nolan Mangini女士拥有宾夕法尼亚大学沃顿商学院(Wharton School at University of Pennsylvania)经济学学士学位,斯坦福大学商学院(Stanford University)工商管理硕士学位和哈佛大学肯尼迪政府学院(Kennedy School of Government)工商管理硕士学位。Nolan Mangini女士是CFA特许持有人。


Siobhan Nolan Mangini has served as Chief Financial Officer since July 2016. Prior to that she served as Vice President, Finance & Business Operations, from October 2015 to July 2016. She joined Castlight in February 2012 and previously served as Senior Director, Financial Planning & Business Operations, from November 2014 to September 2015 and as Director, Strategy & Business Development, from February 2012 to September 2014. Prior to joining Castlight, she worked at Bain & Company, a management consulting company, from 2009 to January 2012 working in the health care and private equity practices. Ms. Nolan Mangini holds a B.S. in Economics from The Wharton School at University of Pennsylvania, an M.B.A. from the Graduate School of Business at Stanford University, and an M.P.A. from The Kennedy School of Government at Harvard University. Ms. Nolan Mangini is a CFA charterholder.
Siobhan Nolan Mangini自2016年7月起担任首席财务官。在此之前,她曾于2015年10月至2016年7月担任财务与业务运营Vice President。她于2012年2月加入Castlight,此前曾担任高级董事,负责财务规划和业务运营(从2014年11月到2015年9月),以及战略和业务发展董事(从2012年2月到2014年9月)。加入Castlight公司之前,她曾任职Bain&Company(管理咨询公司)(从2009年到2012年1月),从事医疗保健和私人股本实践。Nolan Mangini女士拥有宾夕法尼亚大学沃顿商学院(Wharton School at University of Pennsylvania)经济学学士学位,斯坦福大学商学院(Stanford University)工商管理硕士学位和哈佛大学肯尼迪政府学院(Kennedy School of Government)工商管理硕士学位。Nolan Mangini女士是CFA特许持有人。
Siobhan Nolan Mangini has served as Chief Financial Officer since July 2016. Prior to that she served as Vice President, Finance & Business Operations, from October 2015 to July 2016. She joined Castlight in February 2012 and previously served as Senior Director, Financial Planning & Business Operations, from November 2014 to September 2015 and as Director, Strategy & Business Development, from February 2012 to September 2014. Prior to joining Castlight, she worked at Bain & Company, a management consulting company, from 2009 to January 2012 working in the health care and private equity practices. Ms. Nolan Mangini holds a B.S. in Economics from The Wharton School at University of Pennsylvania, an M.B.A. from the Graduate School of Business at Stanford University, and an M.P.A. from The Kennedy School of Government at Harvard University. Ms. Nolan Mangini is a CFA charterholder.
Eric Chan

陈健豪,C.P.A.,自2017年8月加入Castlight以来一直担任首席会计官。最近,陈先生于2015年11月至2017年8月担任软件公司SugarCRM的副总裁兼公司财务总监。从2012年4月到2015年11月,他曾任职Twitter公司(社交媒体公司),在那里他曾担任助理总会计师。在职业生涯早期,Chan先生在普华永道会计师事务所(PricewaterhouseCoopers LLP)和毕马威会计师事务所(KPMG LLP)担任多个审计职位超过10年。Chan先生是一名注册会计师,持有澳大利亚莫纳什大学(Monash University,Australia)会计和金融学位。


Eric Chan, C.P.A., has served as Chief Accounting Officer since he joined Castlight in August 2017. Most recently, Mr. Chan was VP, Corporate Controller at SugarCRM, a software company, from November 2015 to August 2017. From April 2012 to November 2015 Mr. Chan was with Twitter, a social media company, where he was Assistant Controller. Earlier in his career, Mr. Chan served in several audit roles at PricewaterhouseCoopers LLP and KPMG LLP for over 10 years. Mr. Chan is a certified public accountant and holds a degree in Accounting and Finance from Monash University, Australia.
陈健豪,C.P.A.,自2017年8月加入Castlight以来一直担任首席会计官。最近,陈先生于2015年11月至2017年8月担任软件公司SugarCRM的副总裁兼公司财务总监。从2012年4月到2015年11月,他曾任职Twitter公司(社交媒体公司),在那里他曾担任助理总会计师。在职业生涯早期,Chan先生在普华永道会计师事务所(PricewaterhouseCoopers LLP)和毕马威会计师事务所(KPMG LLP)担任多个审计职位超过10年。Chan先生是一名注册会计师,持有澳大利亚莫纳什大学(Monash University,Australia)会计和金融学位。
Eric Chan, C.P.A., has served as Chief Accounting Officer since he joined Castlight in August 2017. Most recently, Mr. Chan was VP, Corporate Controller at SugarCRM, a software company, from November 2015 to August 2017. From April 2012 to November 2015 Mr. Chan was with Twitter, a social media company, where he was Assistant Controller. Earlier in his career, Mr. Chan served in several audit roles at PricewaterhouseCoopers LLP and KPMG LLP for over 10 years. Mr. Chan is a certified public accountant and holds a degree in Accounting and Finance from Monash University, Australia.
John C. Doyle

John C. Doyle,他曾担任我们的首席财务官、副总裁、财务主管(2012年11月以来)。此前,他曾担任 Achaogen公司(一家生物制药公司)的首席财务官兼首席运营官(从2009年8月到2012年11月)。加入Achaogen公司之前,他曾担任Genentech公司的负责财务和公司规划的副总裁(从2007年7月到2009年6月)。他此前曾担任Renovis公司的多种职务,包括财务副总裁兼首席财务官(从2002年8月到2006年8月)、负责财务及运营的高级副总裁和首席财务官(从2006年8月到2007年1月),以及负责公司发展的高级副总裁和首席财务官(从2007年1月到2007年6月)。2012年11月以来,他一直担任 Achaogen公司的董事会成员。他是注册会计师,持有California Polytechnic State University, San Luis Obispo的工商管理学士学位,以及加州大学伯克利分校哈斯商学院(the Haas School of Business at the University of California, Berkeley)的工商管理硕士学位。


John C. Doyle has served as Chief Executive Officer and as a director since April 2017. He previously served as President from July 2016 until April 2017 and as Chief Operating Officer from November 2015 until April 2017. Mr. Doyle also served as Chief Financial Officer, Vice President and Treasurer from November 2012 until July 2016. Previously, Mr. Doyle served as Chief Financial Officer and then Chief Operating Officer of Achaogen, Inc., a biopharmaceutical company, from August 2009 to November 2012. Prior to joining Achaogen, Mr. Doyle was Vice President, Finance and Corporate Planning at Genentech, Inc. from July 2007 to June 2009. Mr. Doyle previously served in various roles at Renovis, Inc., from 2002 to June 2007 ultimately as its Senior Vice President of Corporate Development and Chief Financial Officer. Mr. Doyle has been a member of the board of directors of Achaogen since November 2012 and a member of its compensation committee since January 2016. Mr. Doyle holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo, and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
John C. Doyle,他曾担任我们的首席财务官、副总裁、财务主管(2012年11月以来)。此前,他曾担任 Achaogen公司(一家生物制药公司)的首席财务官兼首席运营官(从2009年8月到2012年11月)。加入Achaogen公司之前,他曾担任Genentech公司的负责财务和公司规划的副总裁(从2007年7月到2009年6月)。他此前曾担任Renovis公司的多种职务,包括财务副总裁兼首席财务官(从2002年8月到2006年8月)、负责财务及运营的高级副总裁和首席财务官(从2006年8月到2007年1月),以及负责公司发展的高级副总裁和首席财务官(从2007年1月到2007年6月)。2012年11月以来,他一直担任 Achaogen公司的董事会成员。他是注册会计师,持有California Polytechnic State University, San Luis Obispo的工商管理学士学位,以及加州大学伯克利分校哈斯商学院(the Haas School of Business at the University of California, Berkeley)的工商管理硕士学位。
John C. Doyle has served as Chief Executive Officer and as a director since April 2017. He previously served as President from July 2016 until April 2017 and as Chief Operating Officer from November 2015 until April 2017. Mr. Doyle also served as Chief Financial Officer, Vice President and Treasurer from November 2012 until July 2016. Previously, Mr. Doyle served as Chief Financial Officer and then Chief Operating Officer of Achaogen, Inc., a biopharmaceutical company, from August 2009 to November 2012. Prior to joining Achaogen, Mr. Doyle was Vice President, Finance and Corporate Planning at Genentech, Inc. from July 2007 to June 2009. Mr. Doyle previously served in various roles at Renovis, Inc., from 2002 to June 2007 ultimately as its Senior Vice President of Corporate Development and Chief Financial Officer. Mr. Doyle has been a member of the board of directors of Achaogen since November 2012 and a member of its compensation committee since January 2016. Mr. Doyle holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo, and an M.B.A. from the Haas School of Business at the University of California, Berkeley.